Gregory D. Perry - 22 Jun 2023 Form 4 Insider Report for Kala Pharmaceuticals, Inc. (KALA)

Reporting relationship: Director
Issuer ticker: KALA
Reported as of: 22 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jun 2023, 20:00:28 UTC
Prior SEC filing: 15 Jun 2023
Next SEC filing: 09 May 2024
Source filing: View source filing
Reporting owner signature: /s/ Mary Reumuth, Attorney-in-Fact

Key filing fact

Gregory D. Perry filed Form 4 for Kala Pharmaceuticals, Inc. (KALA) on 23 Jun 2023.

Key facts

This page summarizes Gregory D. Perry's Form 4 filing for Kala Pharmaceuticals, Inc. (KALA).
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 23 Jun 2023, 20:00.

Change

Previous filing in this sequence was filed on 15 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KALA transaction

Common Stock

Award

Transaction value: $0
Shares: +5,856
Change %: +231%
Price: $0.000000
Shares after: 8,394
Date: 22 Jun 2023
Ownership: Direct
Footnotes: F1, F2

KALA transaction

Common Stock

Award

Transaction value: $0
Shares: +1,100
Change %: +13%
Price: $0.000000
Shares after: 9,494
Date: 22 Jun 2023
Ownership: Direct
Footnotes: F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KALA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +7,808
Change %
Price: $0.000000
Shares after: 7,808
Date: 22 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,808
Exercise price: $14.56
Footnotes: F5

KALA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +2,500
Change %
Price: $0.000000
Shares after: 2,500
Date: 22 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,500
Exercise price: $14.56
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 1/3 of the shares underlying the RSUs on June 22, 2024, as to 1/3 of the shares underlying the RSUs on June 22, 2025 and as to the final 1/3 of shares underlying the RSUs on June 22, 2026.

Footnote F2

Includes 8,394 unvested RSUs.

Footnote F3

Grant of RSUs under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023.

Footnote F4

Includes 9,494 unvested RSUs.

Footnote F5

This option was granted on June 22, 2023 and vests over four years beginning on the vesting commencement date of June 22, 2023, with 25% of the shares underlying the option vesting on June 22, 2024, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter.

Footnote F6

This option was granted on June 22, 2023 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023.